Biomarker risk stratification with capsule sponge in the surveillance of Barrett's oesophagus: prospective evaluation of UK real-world implementation.

Journal: Lancet (London, England)
Published Date:

Abstract

BACKGROUND: Endoscopic surveillance is the clinical standard for Barrett's oesophagus, but its effectiveness is inconsistent. We have developed a test comprising a pan-oesophageal cell collection device coupled with biomarkers to stratify patients into three risk groups. We aimed to prospectively evaluate the prespecified risk stratification tool to establish whether it can identify those at highest risk of dysplasia or cancer to prioritise the timing of endoscopy; and safely be used to follow up the low-risk group, thus sparing patients from unnecessary endoscopies.

Authors

  • W Keith Tan
    Early Cancer Institute, University of Cambridge, Cambridge, United Kingdom of Great Britain and Northern Ireland.
  • Caryn S Ross-Innes
    Early Cancer Institute, Department of Oncology, University of Cambridge, Cambridge, UK.
  • Timothy Somerset
    Early Cancer Institute, Department of Oncology, University of Cambridge, Cambridge, UK.
  • Greta Markert
    Cancer Research UK Cambridge, Cancer Research UK Cambridge Research Institute, Cambridge, United Kingdom of Great Britain and Northern Ireland.
  • Florian Markowetz
    Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge CB2 0RE, UK; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 0RE, UK. Electronic address: florian.markowetz@cruk.cam.ac.uk.
  • Maria O'Donovan
    MRC Cancer Unit, University of Cambridge, Cambridge, UK.
  • Massimiliano di Pietro
    Early Cancer Institute, University of Cambridge, Cambridge, United Kingdom of Great Britain and Northern Ireland.
  • Peter Sasieni
    Cancer Prevention Trials Unit, Queen Mary University of London, London, United Kingdom.
  • Rebecca C Fitzgerald
    MRC Cancer Unit, University of Cambridge, Cambridge, United Kingdom.